H
CPRX icon

HoyleCohen’s Catalyst Pharmaceutical CPRX Stock Holding History

HoyleCohen’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-44,000
Closed -$166K – 167
2018
Q3 		$166K Hold
44,000
– – 0.03% 164
2018
Q2 		$137K Hold
44,000
– – 0.03% 156
2018
Q1 		$105K Hold
44,000
– – 0.02% 150
2017
Q4 		$172K Buy
+44,000
New +$145K 0.03% 149

Other funds holding CPRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HoyleCohen's CPRX Position: Q4 2018 in Review

HoyleCohen sold out of Catalyst Pharmaceutical (CPRX) in Q4 2018, closing a stake of 44,000 shares — an estimated $166K sold.

HoyleCohen first reported a position in CPRX in Q4 2017 and held it in 4 quarters. The position peaked at $172K in Q4 2017. 86 funds tracked by Wall St. Rank hold CPRX as of Q4 2018.

  • HoyleCohen reported no remaining Catalyst Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • HoyleCohen sold 44,000 Catalyst Pharmaceutical shares in Q4 2018, an estimated $166K.
  • HoyleCohen first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 4 quarters.
  • HoyleCohen's Catalyst Pharmaceutical position peaked at $172K in Q4 2017.
  • 86 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2018.

Based on HoyleCohen's 13F filing for Q4 2018, filed 14 Feb 2019.